Skip to content

Main Navigation

test

Search

Keystone Symposium: Viral Immunity: Basic Mechanisms and Therapeutic Applications | Poster #: 1040 | A DNA COVID-19 vaccine candidate targeting antigen-presenting cell and adapted to RBD of emerging SARS-CoV-2 variants induced strong cross-neutralizing antibodies and protective immune responses in mice
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange
Nykode Therapeutics ASA – Prospectus for listing on the main list of the Oslo Stock Exchange
Nykode Therapeutics – approval and publication of prospectus and admission to trading on the Oslo Stock Exchange’s main list
Nykode Therapeutics appoints Klaus Edvardsen as Chief Development Officer

Vaccibody Granted Platform Patent in the US (16.02.15) | Sarsiaseed on Vaccibody Granted Platform Patent in the US
Vaccibody får viktig patent godkjent i USA (16.02.15) | Sarsiaseed on Vaccibody Granted Platform Patent in the US

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
0349 Oslo
Norway
Phone +47 22 95 81 93